Last reviewed · How we verify
NCT05744674
Phase Ⅱ Study of Intercostal Nerve Block With HR18034 for Postsurgical Pain Management
Phase 2 trial testing HR18034 in Thoracoscopic Lobectomy in 96 participants. Status unknown.
30 June 2023
Quick facts
| Lead sponsor | Shanghai Hengrui Pharmaceutical Co., Ltd. |
|---|---|
| Phase | Phase 2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | supportive care |
| Enrollment | 96 |
| Start date | 21 February 2023 |
| Primary completion | 30 June 2023 |
| Estimated completion | 30 June 2023 |
| Sites | 1 location across China |
Drugs / interventions tested
- HR18034 — full drug profile →
- Ropivacaine Hydrochloride Injection
Conditions studied
- Thoracoscopic Lobectomy — all drugs for Thoracoscopic Lobectomy →
Sponsor
Shanghai Hengrui Pharmaceutical Co., Ltd. — full company profile →
Who can join
18 and older, any sex, with Thoracoscopic Lobectomy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Phase Ⅱ, randomized, double-blind, comparator-controlled study to evaluate the efficacy, safety and pharmacokinetics of single injection intercostal nerve block with HR18034 for postoperative pain management compared with ropivacaine.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05744674
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of HR18034
Trials testing the same drug.
- NCT06509958 — Phase Ⅱ Study of Adductor Canal Block With HR18034 for Postsurgical Pain Management in TKA · Phase 2 · terminated
- NCT05769855 — A Study of HR18034 for Postoperative Analgesia in Subjects Undergoing Hemorrhoidectomy · Phase 3 · completed
- NCT05376904 — A Trial of HR18034 for Postoperative Analgesia in Subjects Undergoing Hemorrhoidectomy. · Phase 2 · completed
- NCT04551924 — A Trial of HR18034 in Inguinal Hernia Repair · Phase 1 · unknown
Other recruiting trials for Thoracoscopic Lobectomy
Currently open trials in the same condition.
- NCT06165991 — Liposomal and Standard Bupivacaine in Thoracic Paravertebral Block for Post-Thoracoscopic Pain · Phase 4 · recruiting
Other Shanghai Hengrui Pharmaceutical Co., Ltd. trials
Trials by the same sponsor.
- NCT06877247 — A Mass Balance Study of [14C] SHR6508 in Chinese Hemodialysis Subjects With Secondary Hyperparathyroidism · Phase 1 · completed
- NCT06649292 — SHR-A1904 Compared With Investigator's Choice of Therapy in Claudin18.2 Positive Patitens With Second-line Advanced or M · Phase 3 · recruiting
- NCT06654440 — A Trial of SHR-A2102 for Treatment of Advanced Gynecological Malignancy · Phase 2 · recruiting
- NCT06639347 — A Trial of SHR-A2102 With Antitumor Therapy in Advanced Urothelial Carcinoma · Phase 1, PHASE2 · recruiting
- NCT06605222 — A Trial of SHR-7787 Injection in Patients With Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05744674 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shanghai Hengrui Pharmaceutical Co., Ltd.
- Last refreshed: 15 March 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05744674.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing